ERBB2 and breast cancer: Furthermore, the incidence of local recurrences in patients treated with trastuzumab was low (n=12, 3%) which is noteworthy as HER2-positive breast cancer was associated with an increased risk of local recurrence in the pre-trastuzumab era (25).